Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 21, 2017 09:07 ET | Source: Leap Therapeutics

Leap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer

CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that it has...
June 01, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics to Present at Two Investor Conferences in June

CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
May 17, 2017 17:16 ET | Source: Leap Therapeutics

Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data...
May 12, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics Reports First Quarter 2017 Financial Results

CAMBRIDGE, Mass., May 12, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
April 20, 2017 12:00 ET | Source: Leap Therapeutics

Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that interim...
April 03, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting

CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported non-clinical and...
March 31, 2017 16:36 ET | Source: Leap Therapeutics

Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers

CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
March 29, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics to Present at Two Investor Conferences in April

CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
March 07, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics to Present at 2017 Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
March 01, 2017 18:39 ET | Source: Leap Therapeutics

Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting

CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced preclinical...